Greenwich LifeSciences GLSI 深 沪
已收盘 12-24 16:00:00 美东时间
17.21
+2.640
+18.12%
华盛通- 最 高17.99
- 今 开14.68
- 成交量 46.51万股
- 最 低 14.08
- 昨 收 14.57
- 总市值 2.38亿
- 52周最高 17.99
- 市盈率 静 --
- 换手率 3.36%
- 52周最低 7.78
- 委 比 -15.94%
- 总股本 1385.45万
- 历史最高 158.07
- 量 比 1.42
- 振 幅 26.84%
- 历史最低 3.262
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Greenwich LifeSciences provides updates on its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company outlines its clinical, financing, and partnering strategies, including expanding trial sites globally, cost-saving measures, and a judicious ATM financing approach. FLAMINGO-01 has enrolled over 1,000 patients, with preliminary data showing an 80% reduction in recurrence rates in the non-HLA-A...
12-22 11:00
Greenwich LifeSciences Reports Early FLAMINGO-01 Results Showing 80% Reduction In Cancer Recurrences
A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient non-HLA-A*02 arm of
12-15 19:09
Greenwich Lifesciences Announces Phase 3 FLAMINGO-01 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Has Achieved A Major Milestone By Screening Over 1,000 Patients
Flamingo-01 Progress to DateThe Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the equivalent of 600
12-03 19:05
Greenwich LifeSciences Takes Fight Against Breast Cancer Recurrence Global with Trial Expansion into Portugal
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
09-30 18:12
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
Greenwich LifeSciences has expanded its Phase III FLAMINGO-01 trial to Portugal, with European regulatory approval. In 2022, Portugal saw 9,065 new breast cancer cases, the leading cancer in women. Dr. Luís António Marques da Costa will lead the trial in Portugal. FLAMINGO-01 evaluates GLSI-100, an immunotherapy for HER2 positive breast cancer patients, with 500 HLA-A*02 patients randomized. CEO Snehal Patel expressed excitement about collaborati...
09-30 10:00
Greenwich LifeSciences expands breast cancer trial to Ireland
Greenwich LifeSciences (NASDAQ:GLSI) said it has expanded its Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, to Ireland. The company's applicat...
09-18 18:25
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
The FDA Has Granted Fast Track Designation To Greenwich Lifesciences' GLSI-100 In HLA-A*02 Patient Population
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
09-10 18:03
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences' GLSI-100 immunotherapy has received FDA Fast Track designation for HLA-A*02 breast cancer patients, aiming to prevent metastatic recurrence. This designation may accelerate drug approval via more frequent FDA communication and rolling BLA review. Previously, Phase IIb data showed an 80% reduction in recurrence rates, with no serious adverse events. The Phase III FLAMINGO-01 trial is ongoing, targeting 500 HLA-A*02 patients...
09-10 10:00
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Greenwich LifeSciences announced that Noble Capital Markets has initiated equity research coverage on the company. The company is focused on its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences in HER2 positive patients. The trial aims to enroll up to 750 patients globally and is led by Baylor College of Medicine. For more details, visit the company's website or clinicaltrials.gov.
08-20 13:25
